— peptide / growth —
Stabilized 29-amino-acid GHRH analog (modified GRF 1-29) used in research as a short-acting probe of growth hormone secretion.
Same molecular history as CJC-1295. Pulsatile GHRH receptor activation research. Read more →
From Retail $41 USDT
Member $36.00 USDT
Members save 15% — free to join
Order now to reserve — we'll ship as soon as inventory is replenished.
Research-grade material. Documentation summarizes published literature in third-person scientific context. Not medical advice; not for human consumption.
— Pricing —
All prices in USDT. Crypto pays settle directly to our wallet.
Single vial
Retail $41 USDT
Member $36.00 USDT
Members save 15% — free to join
1 vial · $36.00 USDT per vial
Most flexible
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
5-Pack
Save 15%Retail $176 USDT
Member $153.00 USDT
Members save 15% — free to join
5 vials · $30.60 USDT per vial
Researcher's choice
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
10-Pack
Best valueRetail $256 USDT
Member $223.00 USDT
Members save 15% — free to join
10 vials · $22.30 USDT per vial
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
— The literature —
MOD-GRF binds the GHRH receptor on pituitary somatotrophs, activating Gas, elevating intracellular cAMP, and stimulating release of stored growth hormone. The D-Ala substitution at position 2 protects against cleavage by dipeptidyl peptidase-4, the principal degradative enzyme for the native GHRH sequence. The additional substitutions at positions 8, 15, and 27 provide further proteolytic stability without altering receptor affinity.
The pharmacokinetic profile produces a relatively short receptor exposure of approximately 30 minutes, generating a single growth hormone pulse per dose rather than sustained receptor activation. This profile distinguishes MOD-GRF from the long-acting CJC-1295 with DAC and recapitulates aspects of physiological GHRH dynamics. When combined with ghrelin receptor agonists in research models, MOD-GRF produces synergistic growth hormone release, reflecting the complementary actions of GHRH (driving cAMP-dependent secretion) and ghrelin receptor signaling (mobilizing intracellular calcium through Gq).
All compounds discussed are intended for research use only. Not for human consumption. Research-context information is educational and does not constitute medical advice.
View the full disclaimer →